Regeneron Pharmaceuticals Inc. buy SVB Securities
Start price
27.03.23
/
50%
€769.90
Target price
27.03.24
€905.83
Performance (%)
16.25%
End price
28.03.24
€895.00
Summary
This prediction ended on 28.03.24 with a price of €895.00. The BUY prediction by SVB_Securities finished with a performance of 16.25%. SVB_Securities has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 4.744% | 4.744% | 46.824% | -6.292% |
| iShares Core DAX® | 0.184% | 5.072% | 8.979% | 63.879% |
| iShares Nasdaq 100 | -0.770% | -2.079% | 26.437% | 88.094% |
| iShares Nikkei 225® | 0.733% | -3.346% | 47.887% | 78.014% |
| iShares S&P 500 | -0.166% | 0.904% | 22.974% | 69.449% |
Comments by SVB_Securities for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at SVB Securities from a "market perform" rating to an "outperform" rating. They now have a $976.00 price target on the stock, up previously from $834.00.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von SVB_Securities gewählte maximale Laufzeit wurde überschritten